Leukemia/lymphoma malady

MalaCards: Leukemia/lymphoma, also known as lymphoma/leukemia, is related to chronic myeloid leukemia and adult t-cell leukemia. An important gene associated with Leukemia/lymphoma is TCL1B (T-cell leukemia/lymphoma 1B), and among its related pathways are Immune response IL-22 signaling pathway and Immune response_IL-22 signaling pathway. The drugs isotretinoin and mitoxantrone and the compounds n-(4-hydroxyphenyl)retinamide and ceramide have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and spleen, and related mouse phenotypes are hematopoietic system and embryogenesis.

leukemia/lymphoma 7 lymphoma/leukemia 7

lymphoma 43 leukemia 43

Diseases related to leukemia/lymphoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1251)

id	Related Disease	Score	Top Affiliating Genes
1	chronic myeloid leukemia	39.7	PIK3CG, KITLG, MYC, BCL2, BCR, AXL
2	adult t-cell leukemia	38.6	CNTN2, IL2RA, TRB@, PTHLH
3	t-cell leukemia	38.4	PIK3CG, REL, CNTN2, MYC, RAG1, BCL2
4	hairy cell leukemia	37.1	BCL6, CD80, ITGA4, FLT3, IL2, IL2RA
5	myelodysplastic syndrome	36.9	KITLG, BOK, MVP, XIAP, MPL, MPO
6	leukemia/lymphoma, t-cell	36.8	TRA@, TCL1A, TCL1B, TCL4
7	myelomonocytic leukemia	36.4	RB1, MYC, MPO, MLL, IRF1, FLT3
8	myeloid leukemia	35.9	PIM2, PIK3CA, PIK3CG, PDCD1, KITLG, BUB1
9	acute myeloid leukemia	35.4	PIM2, PIK3CA, PIK3CG, KITLG, BUB1, RB1
10	primary effusion lymphoma	35.3	MYC, BCL6, IL7, TCL1A
11	malt lymphoma	35.2	MYC, BCL10, BCL2, BCL6, ZAP70, CD79A
12	acute monocytic leukemia	35.2	MYC, ZC3H12D, MPO, MLL, FLT3, IDO1
13	down syndrome	35.0	RB1, MYC, MYCN, BCL10, BCL3, BCL6
14	prolymphocytic leukemia	34.9	MYC, ZAP70, ATM, ANPEP, CCND1, HLA-S
15	megakaryoblastic leukemia	34.9	KITLG, MPL, MPO, MLL, FLT3, IL2
16	megakaryocytic leukemia	34.6	KITLG, BCL2, MPO, ANXA5, CASP3, TP53
17	acute lymphocytic leukemia	34.6	RB1, VEGFA, MYC, PAX5, BCL2, BCR
18	chronic myelomonocytic leukemia	34.6	RB1, MPO, FLT3, EZH2, WT1, TOP1
19	monocytic leukemia	34.4	VEGFA, VCAM1, MYC, PARP1, BCL2, ZC3H12D
20	marginal zone b-cell lymphoma	34.3	RB1, PAX5, BCL10, BCL3, BCL6, ATM
21	acute megakaryoblastic leukemia	33.9	MPO, MLL, THPO, RUNX1, GATA1
22	t-cell prolymphocytic leukemia	33.5	VEGFA, ZAP70, ATM, CDKN1B, CD19, CD7
23	acute myelomonocytic leukemia	33.4	MPO, MLL, CSF1, CSF1R, RUNX1
24	myeloproliferative disorder	33.2	KITLG, ZMYM2, BCR, AXL, MPL, MPO
25	central nervous system lymphoma	33.0	RB1, VEGFA, MYC, PAX5, BCL10, BCL2
26	wilms tumor	33.0	BUB1B, VEGFA, MYC, MYCN, BCL2, MVP
27	acute lymphoblastic leukemia	32.9	KITLG, RB1, NBN, MYCN, RAG1, PAX5
28	large granular lymphocyte leukemia	32.9	PIK3CG, CNTN2, BCL2, IL10, IL15, IL2
29	mantle cell lymphoma	32.8	BCL2, BCL6, ATM, MDM2, CCND1, CCNG1
30	acute biphenotypic leukemia	32.7	MPO, MLL, NOTCH1, ABL1, TLX1
31	intraocular lymphoma	32.4	BCL2, BCL6, IL10, IL6, ABCC1, CXCL12
32	lymphomatoid papulosis	32.3	B2M, CD7, GZMB, IRF4, FAS, CCR4
33	acute lymphoblastic leukemia, childhood	32.3	LEP, CDKN2C, CDKN2B, CDKN1B, CDKN2A, MLL
34	thyroid lymphoma	32.3	BCL2, CDKN2B, CDKN2A, IL7, FAS, TP53
35	primary malignant lymphoma	32.2	PIK3CA, CDKN2B, CDKN2A, IL2RB, TP53, PTHLH
36	acquired immunodeficiency syndrome	32.2	BCL2A1, BCL6, LGALS1, B2M, CD274, CD55
37	gastrointestinal lymphoma	32.1	NBN, BCL2, CD44, CCND1, CASP8, TP53
38	lymphoma, diffuse large cell	32.0	MYC, PAX5, BCL2, BCL6, CDKN2B, CD44
39	myelofibrosis	31.9	MPL, FLT3, FGF2, THPO, GATA1
40	hypereosinophilic syndrome	31.9	FGFR1, IL2, IL2RA, IFNA1, IFNA2, TNFSF8
41	leukemia	31.9	PIM2, PIK3CA, PIK3CG, RFC1, PDCD1, PDCD1LG2
42	plasma cell leukemia	31.8	BCL10, CDKN2A, CD40LG, CDK4, IRF4, IL6
43	graft versus host disease	31.7	GZMB, IL10, IL15, IL2, IL2RA, IL2RB
44	t-cell large granular lymphocyte leukemia	31.7	IL10, IL15, IL2RA, IL6, TNF
45	mastocytosis	31.4	PIK3CA, KITLG, BGLAP, BCL2, MPO, FGFR1
46	reticulosarcoma	31.4	PAX5, PARP1, BCL2, BCL3, BCL6, MUC1
47	stem cell leukemia	31.4	ZMYM2, MPO, FLT3, FGFR1, TAL1, RUNX1
48	non-hodgkin lymphoma	31.3	KITLG, NBN, MYC, MYCN, RAG1, ZMYM2
49	acute myeloid leukemia, adult	31.2	MVP, CDKN2B, MLL, FLT3, GSTM1, GSTT1
50	hodgkin's lymphoma	31.2	PIK3CG, REL, RAG1, PAX5, BCL2, BCL3

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 asparaginase, cytarabine, cytarabine liposome, doxorubicin hydrochloride, irinotecan, irinotecan hydrochloride, isotretinoin, methotrexate, methotrexate sodium, mitoxantrone, mitoxantrone hydrochloride, pipobroman, thiotepa, vincristine, vincristine sulfate

MalaCards organs/tissues related to leukemia/lymphoma:

²²

MGI Mouse Phenotypes related to leukemia/lymphoma:

²⁵ (show all 28)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system phenotype	MP:0005397	12.2	PIM2, PDCD1, PDCD1LG2, BUB1, BUB1B, NBN
2	embryogenesis phenotype	MP:0005380	11.2	PIK3CA, REL, BUB1B, NBN, MYC, MYCN
3	nervous system phenotype	MP:0003631	10.9	PDCD1, REL, CNTN2, KITLG, RB1, NBN
4	respiratory system phenotype	MP:0005388	10.8	REL, MYCN, RAG1, RAD50, BCL6, LDHA
5	renal/urinary system phenotype	MP:0005367	10.7	PDCD1, MYCN, RAG1, RASGRP1, BCL2, BCR
6	immune system phenotype	MP:0005387	10.7	PIM2, REL, BUB1, BUB1B, NBN, RASGRP1
7	craniofacial phenotype	MP:0005382	10.6	KITLG, NBN, MYCN, BCL11B, ZEB1, ITGA4
8	hearing/vestibular/ear phenotype	MP:0005377	10.5	KITLG, RB1, MYC, RAG1, PAX5, PARP1
9	other phenotype	MP:0005395	10.5	BUB1, MRE11A, CDKN2A, CD40LG, IL2, TP73
10	endocrine/exocrine gland phenotype	MP:0005379	10.4	BUB1, NBN, RAD50, ZEB1, CDKN2C, CDKN2B
11	no phenotypic analysis	MP:0003012	10.0	PDCD1LG2, BUB1, RB1, VEGFA, VCAM1, MYC
12	pigmentation phenotype	MP:0001186	10.0	KITLG, RB1, MYC, RAG1, BCL2, ZEB1
13	digestive/alimentary phenotype	MP:0005381	9.8	REL, KITLG, RB1, VEGFA, MYC, MYCN
14	integument phenotype	MP:0010771	9.7	PIK3CG, REL, KITLG, BUB1B, RB1, MYC
15	liver/biliary system phenotype	MP:0005370	9.6	REL, BUB1, VEGFA, MYCN, RAG1, RASGRP1
16	mortality/aging	MP:0010768	9.4	PIK3CA, PDCD1, PDCD1LG2, REL, KITLG, RB1
17	growth/size phenotype	MP:0005378	9.4	PIM2, PIK3CA, PIK3CG, REL, KITLG, BUB1
18	normal phenotype	MP:0002873	9.2	BUB1, SEZ6L2, VEGFA, MYC, RAG1, PAX5
19	limbs/digits/tail phenotype	MP:0005371	8.8	KITLG, RB1, VEGFA, MYCN, ZEB1, SCD
20	skeleton phenotype	MP:0005390	8.7	PIK3CG, REL, KITLG, BUB1B, RB1, VEGFA
21	cellular phenotype	MP:0005384	8.7	PIM2, PIK3CA, PIK3CG, PDCD1, PDCD1LG2, REL
22	tumorigenesis	MP:0002006	8.6	PIK3CA, PDCD1LG2, KITLG, BUB1, BUB1B, RB1
23	reproductive system phenotype	MP:0005389	8.6	PIK3CA, BUB1, BUB1B, NBN, VEGFA, MYCN
24	behavior/neurological phenotype	MP:0005386	8.5	PIK3CA, CNTN2, RB1, NBN, SEZ6L2, MYCN
25	homeostasis/metabolism phenotype	MP:0005376	8.0	PIK3CA, PIK3CG, PDCD1LG2, REL, KITLG, BUB1
26	vision/eye phenotype	MP:0005391	7.8	PIK3CA, PDCD1, KITLG, BUB1B, RB1, VEGFA
27	muscle phenotype	MP:0005369	7.7	PIK3CA, PIK3CG, PDCD1, BUB1B, RB1, VEGFA
28	cardiovascular system phenotype	MP:0005385	7.7	PIK3CA, PIK3CG, PDCD1, REL, KITLG, RB1

Articles related to leukemia/lymphoma:

(show top 50)    (show all 213)

id	Title	Authors	Year	Affiliating Genes
1	FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. (21821710)	Elliott N.E.... DavAc U.P.	2011	JAK3
2	Vinblastine induces acute, cell cycle phase-independe nt apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when mcl-1 is suppressed. (20371726)	Salerni B.L.... Eastman A.	2010	BCL2, MCL1
3	The MHC class Ib protein ULBP1 is a nonredundant dete rminant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. (20101024)	LanAsa T.... Silva-Santos B.	2010	ULBP1
4	STAT3 is a substrate of SYK tyrosine kinase in B-line age leukemia/lymphoma cells exposed to oxidative stress. (20133729)	Uckun F.M.... Ozer Z.	2010	SYK, STAT3
5	Constitutional mismatch repair deficiency and childho od leukemia/lymphoma--report on a novel biallelic MSH6 mutation. (20015892)	Ripperger T.... Schlegelberger B.	2010	MSH6
6	In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. (18791162)	Fukumoto R.... Franchini G.	2009	CALR, CANX, IL2RG
7	Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity. (18639341)	Hoshi M.... Seishima M.	2009	IDO1
8	Selective killing of leukemia and lymphoma cells ectopically expressing hCGbeta by a conjugate of curcumin with an antibody against hCGbeta subunit. (19127081)	Vyas H.K.... Talwar G.P.	2009	CGB
9	The process behind the expression of mdr-1/P-gp and m rp/MRP in human leukemia/lymphoma. (19414348)	Hirose M.	2009	ABCC1, ABCB1
10	Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1). (17704792)	Abdul-Hai A.... Slavin S.	2007	IL7
11	Sustained hematologic and central nervous system remi ssion with single-agent denileukin diftitox in refractory adult T-cell leukemia /lymphoma. (17875237)	Evens A.M.... Mehta J.	2007	IFNA1
12	Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. (17550847)	Dbaibo G.S.... Bazarbachi A.	2007	UGCG
13	Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. (17554373)	Nadella M.V.... Rosol T.J.	2007	PTHLH
14	Impairment of double-strand breaks repair and aberrant splicing of ATM and MRE11 in leukemia-lymphoma cell lines with microsatellite instability. (16542220)	Ham M.F.... Aozasa K.	2006	ATM, MRE11A, NBN
15	Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor. (17016779)	Galmarini C.M.	2006	PNP
16	Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma. (16646068)	Shimakage M.... Yutsudo M.	2006	RTN4
17	Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells. (15893691)	Ozdemir O.... Savasan S.	2005	GZMB, PRF1, IL15
18	Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. (15543232)	Nasr R.... Bazarbachi A.	2005	PSMD9
19	Antitumor mechanism of 3-bromopropionylamino benzoylurea on leukemia and lymphoma (15493834)	Li J.N.... Jiang J.D.	2004	CASP3
20	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. (14976040)	Rimsza L.M.... Grogan T.M.	2004	HLA-DRA
21	Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. (15337766)	Liu C.J.... Di Cesare P.E.	2004	HDAC1, COMP, ZBTB7A
22	Adult T cell leukemia lymphoma. (15353320)	Ratner L.	2004	IL2
23	Transcription factor expression in cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. (15369140)	Matsuo Y.... Orita K.	2004	RUNX1, GATA1, IRF1
24	Defucosylated chimeric anti-CC chemokine receptor 4 I gG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therape utic activity to T-cell leukemia and lymphoma. (15026353)	Niwa R.... Shitara K.	2004	CCR4
25	Is B-lineage acute lymphoblastic leukemia with a mature phenotype and l1 morphology a precursor B-lymphoblastic leukemia/lymphoma or Burkitt leukemia/lymphoma? (14521459)	Li S.... Lew G.	2003	MYC
26	Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma. (12543867)	Kimura S.... Maekawa T.	2003	CD79A
27	Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. (12438221)	Oka T.... Akagi T.	2002	PTPN6
28	Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. (12443879)	Shao R.H.... Foss F.M.	2002	PARP1, IL2RA, IL2
29	Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. (11325850)	Tsukasaki K.... Koeffler H.P.	2001	BCL2, TNF, CYP1A1
30	Truncated TSG101 transcripts in human leukemia and lymphoma cell lines. (10664246)	Hosokawa Y.... Seto M.	2000	TSG101
31	Low frequency of expression of dominant-negative Ikaros isoforms in human leukemia and lymphoma cell lines. (10739009)	Hosokawa Y.... Seto M.	2000	IKZF1
32	Electron microscopical analysis of myeloperoxidase of leukemic cells in CD7+ stem cell leukemia/lymphoma. (10359066)	Murakami H.... Karasawa M.	1999	MPO
33	Expression of receptor tyrosine kinase HTK (hepatoma transmembrane kinase) and HTK ligand by human leukemia-lymphoma cell lines. (10221518)	Steube K.G.... Drexler H.G.	1999	EPHB4, EFNB2
34	ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. (9463314)	Stankovic T.... Taylor A.M.R.	1998	ATM
35	CDKN2 (MTS1/p16INK4A) gene alterations in adult T-cell leukemia/lymphoma. (9638973)	Uchida T.... Hotta T.	1998	CDKN2A
36	Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. (9408961)	Valkov N.I.... Sullivan D.M.	1997	TOP1
37	Fas antigen (CD95) expressions and apoptosis of neoplastic cells from various lymphoid malignancies including adult T-cell leukemia/lymphoma (8741700)	Sasao T.... Ichikawa Y.	1996	FAS
38	Multiple interspecies transmissions of human and simian T-cell leukemia/lymphoma virus type I sequences. (8583886)	Crandall K.A.	1996	ERVW-1
39	Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. (7655021)	MorosActti R.... Koeffler H.P.	1995	CDKN1B
40	A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas. (8592572)	MesA!rosovA! A.... BabusA-kovA! O.	1995	ADA, PNP
41	Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. (7528856)	Gruss H.J.... Drexler H.G.	1994	TNFRSF8, TNFSF8
42	Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman. (8180610)	Seymour J.F.... Cabanillas F.	1994	PTHLH
43	Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. (7962324)	Ikeda K.... Saitoh T.	1994	PTHLH
44	Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. (7517719)	Haagen I.A.... de Gast B.C.	1994	CD19, CD80
45	Expression of the FLT3 gene in human leukemia-lymphoma cell lines. (8182945)	DaSilva N.... Drexler H.G.	1994	FLT3
46	Functional conservation of the neutralizing domains o n the external envelope glycoprotein of cosmopolitan and melanesian strains of human T cell leukemia/lymphoma virus type I. (7504032)	Hoshino H.... Yanagihara R.	1993	ERVW-1
47	Expression of myeloid cell phenotypes by a novel adult T-cell leukemia/lymphoma cell line. (1373776)	Koizumi S.... Fukazawa Y.	1992	TRB@
48	Serum deoxythymidine kinase in adult T-cell leukemia-lymphoma and its related disorders. (2016911)	Sadamori N.... Ichimaru M.	1991	TKT
49	An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. (2230878)	Ohno R.... Oguro M.	1990	TOP1
50	Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. Clinical, histopathologic, and immunohistochemical analyses. (2245393)	Nagatani T.... Nakajima H.	1990	CD7

Genes related to leukemia/lymphoma according to GeneCards:

(show top 50)    (show all 237)

id	Symbol	Description	Score	GeneCards Section Context
1	TCL1B	T-cell leukemia/lymphoma 1B	11.1	Orthologs, Aliases & Descriptions, Proteins, Transcripts
2	TCL1A	T-cell leukemia/lymphoma 1A	11.1	Transcripts, Publications, Aliases & Descriptions, Functions
3	ZMYM2	zinc finger, MYM-type 2	11.1	Summaries
4	FGFR1	fibroblast growth factor receptor 1	11.1	Summaries
5	MYC	v-myc myelocytomatosis viral oncogene homolog (avian)	11.1	Publications, Summaries
6	TCL6	T-cell leukemia/lymphoma 6 (non-protein coding)	11.1	Proteins, Aliases & Descriptions, Transcripts
7	TCL4	T-cell leukemia/lymphoma 4	11.1	Functions, Aliases & Descriptions
8	BCL3	B-cell CLL/lymphoma 3	11.1	Aliases & Descriptions, Orthologs
9	ANPEP	alanyl (membrane) aminopeptidase	11.1	Summaries
10	ZBTB7A	zinc finger and BTB domain containing 7A	11.1	Publications, Aliases & Descriptions
11	TLX1	T-cell leukemia homeobox 1	11.1	Publications, Aliases & Descriptions
12	TAL1	T-cell acute lymphocytic leukemia 1	11.1	Aliases & Descriptions, Publications
13	N4BP2	NEDD4 binding protein 2	11.0	Summaries
14	BCL2	B-cell CLL/lymphoma 2	11.0	Orthologs, Publications
15	IL2RA	interleukin 2 receptor, alpha	11.0	Publications
16	TRB@	T cell receptor beta locus	11.0	Publications
17	TRA@	T cell receptor alpha locus	11.0
18	ANXA8L2	annexin A8-like 2	11.0	Publications
19	BRI3BP	BRI3 binding protein	11.0	Expressions
20	TAGLN2	transgelin 2	11.0	Publications
21	CD19	CD19 molecule	11.0	Publications
22	HMHA1	histocompatibility (minor) HA-1	11.0	Expressions
23	TNFRSF18	tumor necrosis factor receptor superfamily, member 18	11.0	Publications
24	HES1	hairy and enhancer of split 1, (Drosophila)	11.0	Publications
25	ZC3H12D	zinc finger CCCH-type containing 12D	11.0	Expressions
26	TNFSF8	tumor necrosis factor (ligand) superfamily, member 8	11.0	Publications
27	CCNG1	cyclin G1	11.0	Publications
28	PIM2	pim-2 oncogene	11.0	Functions
29	DLL1	delta-like 1 (Drosophila)	11.0	Publications
30	CDKN2C	cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)	11.0	Publications
31	PRMT5	protein arginine methyltransferase 5	11.0	Publications
32	EFNB2	ephrin-B2	11.0	Publications
33	EPHB4	EPH receptor B4	11.0	Publications
34	RAG1	recombination activating gene 1	11.0	Publications
35	GAS6	growth arrest-specific 6	11.0	Publications
36	BAG1	BCL2-associated athanogene	11.0	Expressions
37	IKZF1	IKAROS family zinc finger 1 (Ikaros)	11.0	Publications
38	CASP5	caspase 5, apoptosis-related cysteine peptidase	11.0	Publications
39	TNFRSF8	tumor necrosis factor receptor superfamily, member 8	11.0	Publications
40	NOTCH1	notch 1	11.0	Publications
41	MPL	myeloproliferative leukemia virus oncogene	11.0	Publications
42	GZMB	granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)	11.0	Publications
43	FOXP3	forkhead box P3	11.0	Publications
44	MYCN	v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)	11.0	Publications
45	CGB	chorionic gonadotropin, beta polypeptide	11.0	Publications
46	CSF1R	colony stimulating factor 1 receptor	11.0	Publications
47	PRF1	perforin 1 (pore forming protein)	11.0	Publications
48	CNTN2	contactin 2 (axonal)	11.0	Publications
49	CDKN2B	cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	11.0	Publications
50	MCL1	myeloid cell leukemia sequence 1 (BCL2-related)	11.0	Publications

Pathways related to leukemia/lymphoma according to GeneDecks:

(show top 50)    (show all 217)

id	Pathway	Score	Top Affiliating Genes
1	Immune response IL-22 signaling pathway10	11.4	MYC, BCL2, JAK1, IL2, IL2RA, IL2RB
2	Immune response_IL-22 signaling pathway41	11.3	MYC, BCL2, JAK1, IL2, IL2RA, IL2RB
3	p53 Signaling36	11.1	BCL2, ATM, CDK4, MDM2, MAPK8, MAPK10
4	Breast Cancer Regulation by Stathmin136	11.0	AXL, FGF2, MAPK10, CCNG1, TSG101
5	Molecular Mechanisms of Cancer36	10.9	PIK3CG, KITLG, RB1, MYC, RASGRP1, BCL2
6	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types37	10.9	BCL2, GZMB, IL15, IL2, IL2RA, IL2RB
7	PGC1Alpha Pathway36	10.9	BCL2, CD80, IL15, IL2, IL2RB, IL2RG
8	Lymphocyte Signaling3	10.9	PIM2, KITLG, RAG1, PAX5, BCL10, BCL6
9	Apoptosis and Autophagy3	10.8	PIM2, MYC, MYCN, PARP1, BCL10, BCL2
10	Rho Family GTPases36	10.8	KITLG, BCL2, AXL, CD80, ITGA4, ITGAE
11	RAR-Gamma-RXR-Alpha Degradation36	10.7	CD80, IL15, IL2, IL7, MAPK14, MAPK10
12	JNK Pathway36	10.6	KITLG, BCL2, AXL, CD80, FLT3, FGF2
13	p53 signaling pathway20	10.6	ATM, CDKN2A, CDK4, MDM2, FAS, CCND3
14	Cell cycle20	10.6	BUB1, BUB1B, RB1, MYC, ATM, CDKN2C
15	Pancreatic Adenocarcinoma36	10.6	KITLG, RB1, BCL2, AXL, JAK1, CDKN2C
16	Cellular Apoptosis Pathway36	10.5	KITLG, BCL2, ATM, CDKN2A, FGF2, FGFR1
17	Tec Kinases Signaling36	10.5	KITLG, BCL2, JAK1, CD80, ITGA4, ITGAE
18	Mitochondrial Apoptosis36	10.4	KITLG, BCL2, ATM, CDKN2A, FGF2, FGFR1
19	p53 Mediated Apoptosis36	10.4	KITLG, BCL2, ATM, FGF2, FGFR1, MET
20	p38 Signaling36	10.4	KITLG, BCL2, ZAP70, AXL, CD80, FLT3
21	Akt Signaling36	10.4	PIK3CG, AXL, CD80, ITGAE, FLT3, FGFR1
22	STAT3 Pathway36	10.4	MYC, BCL2, CD80, MET, IL10, IL15
23	TGF-Beta Pathway36	10.3	KITLG, BCL2, CD80, FGF2, FGFR1, MET
24	Cell Cycle / Checkpoint Control3	10.3	BUB1B, RB1, NBN, RAD50, MSH6, ATM
25	Hematopoietic cell lineage20	10.3	KITLG, CD59, CD19, CD44, CD7, CD55
26	G1-S Phase Transition36	10.3	RB1, ATM, CDKN2C, CDKN2B, CDKN1B, CDKN2A
27	NFAT in Immune Response36	10.3	KITLG, ZAP70, AXL, CD79A, CD80, FLT3
28	Endothelin-1 Signaling Pathway36	10.2	MYC, AXL, CD80, FLT3, IL10, IL2
29	MAPK Family Pathway36	10.2	KITLG, BCL2, CD80, FGF2, FGFR1, MET
30	Jak-STAT signaling pathway20	10.2	PIK3CA, PIK3CG, MYC, LEP, MPL, JAK1
31	Antioxidant Action of Vitamin-C36	10.1	KITLG, BCL2, CD80, FGF2, FGFR1, MET
32	Chronic myeloid leukemia20	10.1	PIK3CA, PIK3CG, RB1, MYC, BCR, CDKN1B
33	PAK Pathway36	10.1	KITLG, BCL2, CD80, FGF2, FGFR1, MET
34	Immune System38	10.1	PDCD1, PDCD1LG2, REL, VCAM1, BCL10, ULBP1
35	MIF Regulation of Innate Immune Cells36	10.0	BCL2, CD80, IL10, IL15, IL2, IL6
36	JAK-STAT Pathway36	9.9	KITLG, MYC, BCL2, AXL, MPL, JAK1
37	Glucocorticoid Receptor Signaling36	9.9	BCL2, CD80, IL10, IL15, IL18R1, IL2
38	IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types37	9.9	FOXP3, IL10, IL2, IL2RA, IL2RB, IL2RG
39	ERK Signaling36	9.9	KITLG, MYC, ZAP70, AXL, CD80, ITGA4
40	Toxoplasmosis20	9.8	PIK3CA, PIK3CG, BCL2, XIAP, JAK1, CD40LG
41	Colorectal cancer20	9.8	PIK3CG, MSH6, MAPK8, TGFB1
42	Intestinal immune network for IgA production20	9.7	CD40LG, CD80, ITGA4, IL10, IL15, IL2
43	Autoimmune thyroid disease20	9.6	CD40LG, CD80, GZMB, IL10, IL2, FAS
44	MIF Mediated Glucocorticoid Regulation36	9.6	BCL2, CD80, IL10, IL15, IL2, IL6
45	T cell receptor signaling pathway20	9.5	PIK3CA, PIK3CG, PDCD1, RASGRP1, BCL10, ZAP70
46	Allograft rejection20	9.4	CD40LG, CD80, GZMB, IL10, IL2, FAS
47	Pathways in cancer20	9.2	PIK3CA, PIK3CG, RB1, VEGFA, MYC, BCL2
48	Measles20	9.1	PIK3CA, PIK3CG, JAK1, CDKN1B, CDK4, IL2
49	Natural killer cell mediated cytotoxicity20	9.1	PIK3CA, PIK3CG, ULBP1, ZAP70, GZMB, FAS
50	Cytokine-cytokine receptor interaction20	8.1	KITLG, VEGFA, LEP, MPL, CD40LG, FLT3

Compounds related to leukemia/lymphoma according to GeneDecks:

(show top 50)    (show all 450)

id	Compound	Score	Top Affiliating Genes
1	n-(4-hydroxyphenyl)retinamide32	11.3	CNTN2, RB1, MYC, PARP1, BCL2, UGCG
2	ceramide32	11.2	PIK3CA, CNTN2, RB1, LGALS1, UGCG, XIAP
3	agar32	10.9	PIK3CA, CNTN2, KITLG, RB1, MYCN, LGALS1
4	phosphatidylserine32 9 9	12.9	PARP1, BCL2, LGALS1, ZAP70, AXL, CD79A
5	vincristine32 34 9 9	13.9	MYCN, BCL6, UGCG, CGB, ITGA4, MLL
6	pge232	10.8	VCAM1, FOXP3, IRF1, FGF2, MAPK10, CCL27
7	flavopiridol32 9 9	12.5	PIK3CG, RB1, VEGFA, PARP1, BCL2, XIAP
8	gp 13032	10.4	BCR, MPL, JAK1, FLT3, IL15, IL18R1
9	ns 39832 42	11.4	PIK3CG, BGLAP, PARP1, CDKN1B, FGF2, MAPK8
10	mitomycin c32	10.4	RB1, NBN, VCAM1, MVP, XIAP, ATM
11	calcitriol32 42 9 18 9	14.4	KITLG, RB1, MYC, BGLAP, PAX5, XIAP
12	daunorubicin32 9 9	12.3	KITLG, MYC, BCL2, MVP, XIAP, MPO
13	oxygen32 18	11.2	CNTN2, KITLG, RB1, BOK, PARP1, BCL2
14	bleomycin32 9 9	12.1	MVP, CGB, ATM, CD44, GSTM1, GSTP1
15	celecoxib32 42 34 9 18 9	15.1	PIK3CG, VEGFA, PARP1, BCL2, CDKN1B, MMP9
16	rituximab32 34 9 9	13.1	PAX5, BCL2, BCL6, BCR, ZAP70, XIAP
17	zoledronic acid32	10.0	BGLAP, PAX5, PARP1, MMP9, IL2, ANXA5
18	atp32	10.0	PIK3CA, RFC1, RB1, RAD50, PARP1, BCR
19	epinephrine32 9 18 9	13.0	KITLG, LEP, MVP, CD79A, MMP9, FAS
20	suberoylanilide hydroxamic acid32	9.9	MYC, PARP1, BCL2, XIAP, IRF1, FGFR1
21	calcium32 9 18 9	12.8	REL, CNTN2, KITLG, RB1, RASGRP1, BGLAP
22	doxorubicin32 34 9 9	12.7	PIK3CA, PIK3CG, KITLG, BUB1B, NBN, MYCN
23	paclitaxel32 34 9 9	12.6	PIK3CA, PIK3CG, KITLG, BUB1, BUB1B, RB1
24	polysaccharide32	9.6	KITLG, VCAM1, LGALS1, B2M, CD79A, CD40LG
25	tetracycline32 9 9	11.6	CNTN2, RB1, MYCN, BGLAP, CDKN2A, CD40LG
26	histamine32 18	10.6	PIK3CA, KITLG, VCAM1, BGLAP, MPO, CD79A
27	glutamate32	9.6	PIK3CA, CNTN2, BCL2A1, LEP, MTHFR, XIAP
28	parthenolide32	9.5	PIK3CG, VCAM1, MMP9, IL6, MAPK8, MAPK14
29	matrigel32	9.5	PIK3CA, PIK3CG, RB1, VEGFA, VCAM1, LGALS1
30	adenylate32	9.5	PIK3CA, PIK3CG, KITLG, VCAM1, CD40LG, CD44
31	zidovudine32 9 9	11.3	CNTN2, KITLG, MYC, B2M, IL10, IL2
32	15-deoxy-delta-12,14-prostaglandin j232	9.3	PIK3CG, VEGFA, VCAM1, MYC, JAK1, FGF2
33	arginine32	9.2	PIK3CA, RFC1, CNTN2, BGLAP, LGALS1, LEP
34	tacrolimus32 34 9 9	12.1	PIK3CA, REL, MYC, BCL2A1, QDPR, CD79A
35	sb 20358032 42	10.0	RB1, VEGFA, VCAM1, BGLAP, PARP1, BCL2
36	curcumin32	9.0	PIK3CG, VEGFA, VCAM1, MYC, PARP1, BCL2
37	triptolide32	9.0	VEGFA, PARP1, BCL2, IL2, IL6, ANXA5
38	neopterin32	8.9	B2M, QDPR, CD79A, CD40LG, GZMB, IL10
39	2,5-oligoadenylate32	8.8	MYC, B2M, IRF1, IL10, IL2, IL2RA
40	cysteine32	8.7	REL, CNTN2, RAG1, BGLAP, PARP1, LGALS1
41	okt332	8.7	VCAM1, ZAP70, CD79A, CD40LG, IL10, IL15
42	cisplatin32 34 9 9	11.6	PIK3CA, KITLG, RB1, VEGFA, MYC, MYCN
43	5fluorouracil32	8.6	PIK3CA, PIK3CG, KITLG, RB1, VEGFA, BCL2
44	gm-csf32	8.4	KITLG, VEGFA, IL10, IL15, IL2, IL6
45	infliximab32 9 9	10.3	VEGFA, BGLAP, ITGA4, FGF2, IL10, IL15
46	alanine32	8.2	RFC1, CNTN2, KITLG, VCAM1, MYC, RAG1
47	vitamin d32	8.2	BGLAP, PAX5, ZEB1, BAG1, MTHFR, B2M
48	cholesterol32 9 18 9	11.1	PIK3CA, KITLG, RB1, VCAM1, PAX5, BCR
49	actinomycin d32	7.8	PIK3CA, PIK3CG, KITLG, RB1, VEGFA, MYC
50	dexamethasone32 42 34 9 9	10.9	PIK3CA, REL, KITLG, RB1, VEGFA, VCAM1

Cellular components related to leukemia/lymphoma according to GeneDecks:

(show all 12)

id	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:005654	10.8	GATA2, CCND1, MCL1, CASP3, TP53, NR3C1
2	integral to plasma membrane	GO:005887	10.4	HLA-B, HLA-A, MET, TFR2, CNTN2, MUC1
3	protein complex	GO:043234	10.0	ALB, TP53, NR3C1, RTN4, MDM2, FOXP3
4	nucleus	GO:005634	9.9	BCL2, BCL11B, BCL10, PARP1, PAX5, RAG1
5	cytoplasm	GO:005737	9.6	BCL10, CXCR3, CPQ, ADA, HDAC1, GAS6
6	external side of plasma membrane	GO:009897	9.5	ANXA5, ENOX2, ANPEP, CCR4, ICAM1, CALR
7	cell surface	GO:009986	9.5	FLT3, CALR, TNF, TGFB1, DPP4, CSF1R
8	plasma membrane	GO:005886	9.1	MPL, CD79A, CD59, CD40LG, CD80, CD19
9	cytosol	GO:005829	8.8	STMN1, PSMD9, PRMT5, HDAC1, PIK3CA, QDPR
10	membrane	GO:016020	8.5	CCND3, CCND1, HLA-B, PTPN6, NR3C1, ABCB1
11	extracellular region	GO:005576	7.0	TNFSF11, TNFRSF18, ERAP1, CALCA, ALB, IFNG
12	extracellular space	GO:005615	6.8	TNFSF11, IL15, IL10, MET, FGF2, MMP9

Biological processes related to leukemia/lymphoma according to GeneDecks:

(show top 50)    (show all 70)

id	Name	GO ID	Score	Top Affiliating Genes
1	cell proliferation	GO:008283	11.6	ZEB1, STIL, BUB1B, GAS6, TNFSF8, TP53
2	response to DNA damage stimulus	GO:006974	11.3	BCL2, CTLA4, TP53, MYC, CCND1, TP73
3	induction of apoptosis by intracellular signals	GO:008629	11.2	MYC, CYCS, TP53, CASP8, CASP3, MAPK8
4	B cell receptor signaling pathway	GO:050853	11.0	CD79A, SYK, PTPN6, CTLA4, CD19, PTPRC
5	apoptotic process	GO:006915	10.9	EBAG9, RTN4, CXCR3, PRF1, PSMD9, ABL1
6	negative regulation of cell growth	GO:030308	10.8	BCL2, RTN4, RB1, WT1, BCL6, ZC3H12D
7	peptidyl-tyrosine phosphorylation	GO:018108	10.8	FGFR1, FLT3, JAK1, ZAP70, PTPN6, ABL1
8	negative regulation of transcription, DNA-dependent	GO:045892	10.8	TP53, PFDN5, TSG101, HDAC1, TGFB1, GAS6
9	activation of pro-apoptotic gene products	GO:008633	10.8	TNFRSF10B, CASP8, FAS, GZMB, BCL2, MYC
10	B cell differentiation	GO:030183	10.7	CD79A, BCL6, CD40LG, ITGA4, FLT3, IL10
11	organ morphogenesis	GO:009887	10.7	TNFSF11, TNF, EFNB2, SYK, COMP, NRP1
12	positive regulation of B cell proliferation	GO:030890	10.7	BCL6, CD40LG, ADA, PTPRC, IL7, IL2
13	signal transduction	GO:007165	10.7	CDK4, FGF2, MET, IL15, TNFSF8, CD274
14	cell surface receptor signaling pathway	GO:007166	10.6	MPL, CD274, BAG1, CD59, CD19, MET
15	hemopoiesis	GO:030097	10.6	IL10, DLL1, KITLG, TAL1, CSF1, CSF1R
16	cellular response to mechanical stimulus	GO:071260	10.6	BCL10, TNFRSF8, CASP8, CASP5, MAPK8, FAS
17	cell-cell signaling	GO:007267	10.5	EFNB2, IFNA2, IL10, IL15, IL2, IL7
18	leukocyte cell-cell adhesion	GO:007159	10.5	VCAM1, CD40LG, ICAM1, CALCA, ITGA4, PTPRC
19	cell cycle arrest	GO:007050	10.5	GAS6, TGFB1, CDKN2B, TP73, TSG101, TP53
20	T cell activation	GO:042110	10.5	DPP4, FOXP3, ADA, CD7, IRF4, CD80
21	negative regulation of cell proliferation	GO:008285	10.5	TSG101, GATA1, BCL11B, BCL6, ZEB1, CDKN2C
22	T cell costimulation	GO:031295	10.4	PDCD1, CD80, PDCD1LG2, DPP4, PIK3CA, CTLA4
23	virus-host interaction	GO:019048	10.4	TP53, MDM2, HLA-B, HLA-A, CASP8, ANPEP
24	negative regulation of transcription from RNA polymerase II promoter	GO:000122	10.3	GATA2, HDAC1, STAT3, FGFR1, BCL6, PARP1
25	immune response	GO:006955	10.3	IL2, CSF3, CXCL12, HFE, NOTCH1, PNP
26	B cell proliferation	GO:042100	10.3	PTPRC, BCL2, CD79A, CD40LG, IL10
27	anti-apoptosis	GO:006916	10.3	TNFRSF18, NR3C1, COMP, HDAC1, MUC1, BCL2A1
28	G1 phase of mitotic cell cycle	GO:000080	10.3	CDKN2C, CDKN2B, CDKN1B, CDKN2A, CDK4, CCND1
29	cell adhesion	GO:007155	10.2	ITGAE, IL2, MADCAM1, ICAM1, NRP1, ABL1
30	regulation of immune response	GO:050776	10.2	CD19, CD40LG, ULBP1, BCL6, B2M, ITGA4
31	protein import into nucleus, translocation	GO:000060	10.2	TNPO1, BCL3, BCL6, IFNG, TGFB1, TNF
32	positive regulation of T cell proliferation	GO:042102	10.0	PNP, HES1, IL6, IL15, PDCD1LG2, VCAM1
33	positive regulation of transcription, DNA-dependent	GO:045893	10.0	TAL1, FOXP3, CD80, CDKN2A, BCL3, PIM2
34	angiogenesis	GO:001525	10.0	ARHGAP24, VEGFA, PIK3CG, PIK3CA, PTEN, ERAP1
35	positive regulation of MAP kinase activity	GO:043406	9.9	TNF, TGFB1, PIK3CG, KITLG, VEGFA, TNFSF11
36	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	9.8	CASP8, TNF, TNFRSF10B, FAS, CDKN2A, CDKN1B
37	induction of apoptosis	GO:006917	9.8	TNF, PTEN, BOK, BCL10, BCL2L13, CDKN2C
38	humoral immune response	GO:006959	9.5	TNF, IFNG, IL7, IL6, BCL2, PAX5
39	interferon-gamma-mediated signaling pathway	GO:060333	9.5	VCAM1, B2M, JAK1, CD44, IRF1, IRF4
40	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.5	TP53, CD80, CD44, NRP1, SYK, GATA1
41	positive regulation of peptidyl-serine phosphorylation	GO:033138	9.4	BCL2, VEGFA, GAS6, IL6, TNF, MET
42	blood coagulation	GO:007596	9.4	IRF1, THPO, CD59, IFNA2, MAPK14, TGFB1
43	positive regulation of transcription from RNA polymerase II promoter	GO:045944	9.3	RB1, VEGFA, MYC, MYCN, PAX5, BCL11B
44	positive regulation of cell proliferation	GO:008284	9.2	HES1, PTPN6, LEP, MYC, VEGFA, NBN
45	response to drug	GO:042493	9.2	ABCG2, ABCC1, ABCB1, PNP, TNF, CALR
46	inflammatory response	GO:006954	9.1	IFNA2, CALCA, TP73, TNF, TGFB1, CSF1
47	negative regulation of apoptotic process	GO:043066	9.0	MAPK8, GATA1, GAS6, HDAC1, CXCL12, STIL
48	platelet activation	GO:030168	8.9	ALB, MPL, AXL, RASGRP1, VEGFA, PIK3CG
49	cytokine-mediated signaling pathway	GO:019221	8.7	CD44, UBE2N, IRF1, CSF3, B2M, JAK1
50	response to hypoxia	GO:001666	8.7	TGFB1, DPP4, CXCL12, ADA, FAS, TNF

Molecular functions related to leukemia/lymphoma according to GeneDecks:

(show all 10)

id	Name	GO ID	Score	Top Affiliating Genes
1	transcription factor binding	GO:008134	10.8	GATA2, BCL10, HES1, BCL2, BCL3, ZEB1
2	cyclin-dependent protein kinase inhibitor activity	GO:004861	10.7	CDKN2C, CDKN1B, CDKN2A, CASP3, CDKN2B
3	tumor necrosis factor receptor binding	GO:005164	10.3	TNFSF8, TNFSF11, ERAP1, CD40LG, CASP8, TNF
4	sequence-specific DNA binding transcription factor activity	GO:003700	10.3	MYC, NR3C1, TP73, TP53, IRF4, IRF1
5	protein kinase binding	GO:019901	10.2	CDKN2C, STAT3, SYK, PTPRC, BCL10, CDKN2B
6	chromatin binding	GO:003682	10.2	BCL6, ZEB1, MSH6, MPO, EZH2, TP53
7	protein homodimerization activity	GO:042803	9.1	CSF1R, NR3C1, ABCG2, HES1, TKT, TGFB1
8	protein binding	GO:005515	8.7	CASP3, MAPK8, FAS, MDM2, IL7, IL2RG
9	cytokine activity	GO:005125	8.6	IFNA2, IL7, IL6, IL2, KITLG, IL15
10	growth factor activity	GO:008083	8.6	LEP, FGF2, VEGFA, IL10, IL2, IL6